Dalbavancin

Antibiotic Class:

Glycopeptide

Antimicrobial Spectrum:

Staphylococcus aureus (Oritavancin susceptible), Coagulase negative Staphylococci, Streptococcus pneumoniae, Streptococcus spp., Enterococcus spp. (Oritavancin susceptible), C. jeikeium, Clostridium spp. (except clostridioforme),, Actinomyces, Propionibacterium spp.,

Mechanism of Action:

Oritavancin inhibits the bacterial cell wall biosynthesis by binding to the C-terminal of the D-alanyl-D-alanine peptidoglycan chain

Pharmacodynamics:

No data

Pharmacokinetics:

Phase III studies ongoing

Adverse Effects:

Studies ongoing

Dosage:

Not commercially available

Disease state based dosing:

Not yet determined

Contraindications/Warnings/Precautions:

Not yet determined

Drug Interactions:

Unknown

Pregnancy:

Unknown

Monitoring Requirements:

Therapeutic:  Culture and sensitivities, serum levels, signs and symptoms of infection, white blood cell count

Brand names/Manufacturer: 

Not currently available